Turning the Tide in Lymphoma Treatment with CAR-DNT Cells
Dr. Wenbin Qian's team found that off-the-shelf CAR-engineered double-negative T cells were well tolerated in an early trial for relapsed large B-cell lymphoma, with promising responses at higher doses.